高危前列腺癌新辅助治疗后[68Ga]PSMA PET/CT反应与生化进展的关联
本研究纳入两项II期临床试验中75例接受新辅助治疗(雄激素剥夺治疗联合多西他赛或多阿比特龙)后行根治性前列腺切除术的高危前列腺癌患者,分析[68Ga]PSMA PET/CT变化与生化无进展生存期(bPFS)的关联。中位随访30个月,18例(24%)出现生化进展。多因素Cox回归显示,仅治疗后[68Ga]PSMA PET/CT的SUVmax和最终病理反应是bPFS的独立预测因素,风险比分别为1.02(95%CI 1.00-1.04;P=0.02)和0.12(95%CI 0.02-0.98;P=0.048)。
要点
- 中位随访30个月,75例高危前列腺癌患者中18例(24%)出现生化进展。
- 治疗后[68Ga]PSMA PET/CT的SUVmax是bPFS独立预测因素,HR为1.02(95%CI 1.00-1.04;P=0.02)。
- 最终病理反应是bPFS独立预测因素,HR为0.12(95%CI 0.02-0.98;P=0.048)。
核心结论
- [68Ga]PSMA PET/CT反应是高危前列腺癌接受新辅助治疗和根治性前列腺切除术后bPFS的独立风险因素,提示[68Ga]PSMA PET/CT是监测新辅助治疗反应的理想工具。
研究设计与样本
- 纳入两项II期临床试验中75例接受新辅助治疗后行根治性前列腺切除术的高危前列腺癌患者,所有患者在新辅助治疗前后均行系列[68Ga]PSMA PET/CT扫描。
主要发现
- 中位随访30个月,18例(24%)出现生化进展。
- 多因素Cox回归显示,仅治疗后[68Ga]PSMA PET/CT的SUVmax和最终病理反应是bPFS的独立预测因素,风险比分别为1.02(95%CI 1.00-1.04;P=0.02)和0.12(95%CI 0.02-0.98;P=0.048)。
- Kaplan-Meier分析显示,[68Ga]PSMA PET/CT反应良好(治疗后SUVmax<8.5)或病理反应良好(病理完全缓解或微小残留病灶)的患者3年生化进展率显著更低。
关键数值与推荐
- 多因素Cox回归中,治疗后[68Ga]PSMA PET/CT的SUVmax的HR为1.02(95%CI 1.00-1.04;P=0.02)。
- 多因素Cox回归中,最终病理反应的HR为0.12(95%CI 0.02-0.98;P=0.048)。
- [68Ga]PSMA PET/CT反应良好定义为治疗后SUVmax<8.5。
- 病理反应良好定义为病理完全缓解或微小残留病灶。
- 新辅助治疗方案为雄激素剥夺治疗联合多西他赛(n=33)或雄激素剥夺治疗联合多阿比特龙(n=42)。
临床怎么用
- 作者认为[68Ga]PSMA PET/CT是监测高危前列腺癌新辅助治疗反应的理想工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our previous study found that the prostate-specific membrane antigen (PSMA) PET/CT response of primary prostate cancer (PCa) to neoadjuvant therapy can predict the pathologic response. This study was designed to investigate the association between [68Ga]PSMA PET/CT changes and biochemical progression-free survival (bPFS) in high-risk patients who underwent neoadjuvant therapy before radical prostatectomy (RP). Methods: Seventy-five patients with high-risk PCa in 2 phase II clinical trials who received neoadjuvant therapy before RP were included. The patients received androgen deprivation therapy plus docetaxel (n = 33) or androgen deprivation therapy plus abiraterone (n = 42) as neoadjuvant treatment. All patients had serial [68Ga]PSMA PET/CT scans before and after neoadjuvant therapy. Age, initial prostate-specific antigen level, nadir prostate-specific antigen level before RP, tumor grade at biopsy, treatment regimen, clinical T stage, PET imaging features, pathologic N stage, and pathologic response on final pathology were included for univariate and multivariate Cox regression analyses to identify independent predictors of bPFS. Results: With a median follow-up of 30 mo, 18 patients (24%) experienced biochemical progression. Multivariate Cox regression analyses revealed that only SUVmax derived from posttreatment [68Ga]PSMA PET/CT and pathologic response on final pathology were independent factors for the prediction of bPFS, with hazard ratios of 1.02 (95% CI, 1.00-1.04; P = 0.02) and 0.12 (95% CI, 0.02-0.98; P = 0.048), respectively. Kaplan-Meier analysis revealed that patients with a favorable [68Ga]PSMA PET/CT response (posttreatment SUVmax < 8.5) or a favorable pathologic response (pathologic complete response or minimal residual disease) had a significantly lower rate of 3-y biochemical progression. Conclusion: Our results indicated that [68Ga]PSMA PET/CT response was an independent risk factor for the prediction of bPFS in patients with high-risk PCa receiving neoadjuvant therapy and RP, suggesting [68Ga]PSMA PET/CT to be an ideal tool to monitor response to neoadjuvant therapy.
引用
- Chen M, Fu Y, Peng S, et al. The Association Between [68Ga]PSMA PET/CT Response and Biochemical Progression in Patients with High-Risk Prostate Cancer Receiving Neoadjuvant Therapy. J Nucl Med. 2023. PMID: 37474268. doi:10.2967/jnumed.122.265368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。